                         SEQUENCE LISTING

<110>  VRIJE UNIVERSITEIT BRUSSEL
 
<120>  RADIO	-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PREVENTION 
       AND/OR TREATMENT OF CANCER

<130>  VUB-064-PCT

<150>  14178943.8
<151>  2014-07-29

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 sequence of VHH 2Rs15d

<400>  1

Gly Tyr Ile Phe Asn Ser Cys Gly 
1               5               


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 sequence of VHH 2Rs15d

<400>  2

Ile Ser Gly Asp Gly Asp Thr 
1               5           


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 sequence of VHH 2Rs15d

<400>  3

Ala Val Cys Tyr Asn Leu Glu Thr Tyr 
1               5                   


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 sequence of VHH 2Rb17c

<400>  4

Gly Phe Ile Phe Ser Asn Asp Ala 
1               5               


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 sequence of VHH 2Rb17c

<400>  5

Ile Asn Trp Ser Gly Thr His Thr 
1               5               


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 sequence of VHH 2Rb17c

<400>  6

Val Thr Gly Tyr Gly Val Thr Lys Thr Pro 
1               5                   10  


<210>  7
<211>  115
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VHH sequence 2Rs15d

<400>  7

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Thr Cys Ala Ala Ser Gly Tyr Ile Phe Asn Ser Cys 
            20                  25                  30          


Gly Met Gly Trp Tyr Arg Gln Ser Pro Gly Arg Glu Arg Glu Leu Val 
        35                  40                  45              


Ser Arg Ile Ser Gly Asp Gly Asp Thr Trp His Lys Glu Ser Val Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Gln Asp Asn Val Lys Lys Thr Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Phe Cys Ala 
                85                  90                  95      


Val Cys Tyr Asn Leu Glu Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  8
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VHH sequence 2Rb17c

<400>  8

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asn Asp 
            20                  25                  30          


Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Asn Trp Ser Gly Thr His Thr Asn Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Arg Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Lys Asp Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Val Thr Gly Tyr Gly Val Thr Lys Thr Pro Thr Gly Gln Gly Thr Gln 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  9
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  His-tag

<400>  9

His His His His His His 
1               5       


<210>  10
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Myc-His-tag

<400>  10

Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala 
1               5                   10                  15      


Ala His His His His His His 
            20              


